William G. Wierda, MD, PhD

Articles

Dr. Wierda on the Fixed-Duration Cohort Results of CAPTIVATE Trial in CLL

September 20th 2021

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Wierda on the Results of the CAPTIVATE Trial in CLL and SLL

December 5th 2020

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Wierda on Chemoimmunotherapy in CLL

December 6th 2019

William G. Wierda, MD, PhD, discusses the use of chemoimmunotherapy in treating patients with chronic lymphocytic leukemia.

Dr. Wierda on the ASCEND Trial and BTK Inhibitor-Based Therapies in CLL

October 25th 2019

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL

October 21st 2019

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda on Role of Rituximab Biosimilar in Evolving CLL Treatment Paradigm

October 14th 2019

William G. Wierda, MD, PhD, discusses the role of the rituximab biosimilar in the chronic lymphocytic leukemia treatment paradigm.

Dr. Wierda on Novel Therapies in Relapsed/Refractory CLL

March 13th 2019

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel therapies in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Wierda on Treatment of Relapsed/Refractory CLL

March 7th 2019

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Wierda Discusses Use of CAR T Cells in CLL

March 2nd 2019

William G. Wierda, MD, PhD, discusses how CAR T cells could become more effective in the treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda Discusses Sequencing New Agents in CLL

October 17th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia.

Dr. Wierda Discusses the Role of Ibrutinib in CLL

October 11th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda Discusses the Need for Newer Therapies in CLL

October 11th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for newer therapies in the treatment of chronic lymphocytic leukemia.

Dr. Wierda Discusses Trials of Novel Combinations in CLL

October 7th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

Dr. Wierda on the Need for Continuous Treatment for CLL

May 5th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for continuous treatments for patients with chronic lymphocytic leukemia (CLL).

Dr. Wierda on Ibrutinib Plus Venetoclax in CLL

February 22nd 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

Dr. Wierda on Factors to Consider in Frontline Management of CLL

December 1st 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses factors that physicians should take into account when administering frontline treatment options to patients with chronic lymphocytic leukemia.

Dr. Wierda on Frontline Management of Patients With CLL

October 31st 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the management of patients with chronic lymphocytic leukemia (CLL) in the firstline setting.

Dr. William Wierda on Role for Ibrutinib in Frontline CLL

October 3rd 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.

Dr. Wierda on Immunotherapy Agents for Patients With CLL

May 31st 2016

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

Dr. Wierda on Minimal Residual Disease in CLL

September 17th 2015

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses minimal residual disease in chronic lymphocytic leukemia (CLL). 

NEXT PAGE
PREVIOUS PAGE